Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab plus chemoradiotherapy for T4a laryngeal carcinoma (Phase II, single-arm)
ChiCTR2600124691Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of finotonlimab in laryngeal squamous cell carcinoma (LSCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 3-year Overall Survival Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
finotonlimab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on ChiCTR2600124691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124691.